Literature DB >> 28181209

Heparin modification of a biomimetic bone matrix modulates osteogenic and angiogenic cell response in vitro.

M Quade, S Knaack, D Weber, U König, B Paul, P Simon, A Rösen-Wolff, R Schwartz-Albiez, M Gelinsky, A Lode1.   

Abstract

In this study, the effect of heparin-modified collagen type I/hydroxyapatite (HA) nanocomposites on key processes of bone regeneration - osteogenesis and angiogenesis - was characterised in vitro. Two approaches were applied for heparin modification: it was either integrated during material synthesis (in situ) or added to the porous scaffolds after their fabrication (post). Cultivation of human bone marrow-derived stromal cells (hBMSC), in heparin-modified versus heparin-free scaffolds, revealed a positive effect of the heparin modification on their proliferation and osteogenic differentiation. The amount of heparin rather than the method used for modification influenced the cell response favouring proliferation at smaller amount (30 mg/g collagen) and differentiation at larger amount (150 mg/g collagen). A co-culture of human umbilical vein endothelial cells (HUVEC) and osteogenically induced hBMSC was applied for in vitro angiogenesis studies. Pre-vascular networks have formed in the porous structure of scaffolds which were not modified with heparin or modified with a low amount of heparin (30 mg/g collagen). The modification with higher heparin quantities seemed to inhibit tubule formation. Pre-loading of the scaffolds with VEGF influenced formation and stability of the pre-vascular structures depending on the presence of heparin: In heparin-free scaffolds, induction of tubule formation and sprouting was more pronounced whereas heparin-modified scaffolds seemed to promote stabilisation of the pre-vascular structures. In conclusion, the modification of mineralised collagen with heparin by using both approaches was found to modulate cellular processes essential for bone regeneration; the amount of heparin has been identified to be crucial to direct cell responses.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28181209     DOI: 10.22203/eCM.v033a08

Source DB:  PubMed          Journal:  Eur Cell Mater        ISSN: 1473-2262            Impact factor:   3.942


  6 in total

Review 1.  Effect of Angiogenesis in Bone Tissue Engineering.

Authors:  Jianhao Huang; Qixiu Han; Meng Cai; Jie Zhu; Lan Li; Lingfeng Yu; Zhen Wang; Gentao Fan; Yan Zhu; Jingwei Lu; Guangxin Zhou
Journal:  Ann Biomed Eng       Date:  2022-05-07       Impact factor: 3.934

Review 2.  The Auxiliary Role of Heparin in Bone Regeneration and its Application in Bone Substitute Materials.

Authors:  Jing Wang; Lan Xiao; Weiqun Wang; Dingmei Zhang; Yaping Ma; Yi Zhang; Xin Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-05-12

3.  Osteogenic and Angiogenic Properties of Heparin as a System for Delivery of Biomolecules for Bone Bioengineering: a Brief Critical Review.

Authors:  L S Litvinova; K A Yurova; O G Khaziakhmatova; M Yu Khlusova; V V Malashchenko; E O Shunkin; N M Todosenko; I K Norkin; P A Ivanov; I A Khlusov
Journal:  Biochem Mosc Suppl B Biomed Chem       Date:  2021-05-14

4.  Bone healing study of alendronate combined with enoxaparin sodium bone cement in rabbits with bone defects.

Authors:  Zhihang Xiao; Dehao Fu; Li Zhang; Weiye Fan; Xiaoyu Shen; Xiangbei Qi
Journal:  J Orthop Surg Res       Date:  2022-09-29       Impact factor: 2.677

5.  Characterization of Naturally Occurring Bioactive Factor Mixtures for Bone Regeneration.

Authors:  Henriette Bretschneider; Mandy Quade; Anja Lode; Michael Gelinsky; Stefan Rammelt; Stefan Zwingenberger; Klaus-Dieter Schaser; Corina Vater
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

6.  Chemotactic and Angiogenic Potential of Mineralized Collagen Scaffolds Functionalized with Naturally Occurring Bioactive Factor Mixtures to Stimulate Bone Regeneration.

Authors:  Henriette Bretschneider; Mandy Quade; Anja Lode; Michael Gelinsky; Stefan Rammelt; Corina Vater
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.